Menu Search
Equities

Absci Corp

ABSI:NSQ

Absci Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.64
  • Today's Change-0.64 / -14.95%
  • Shares traded2.21m
  • 1 Year change+186.61%
  • Beta2.1962
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Absci Corp's net income fell 5.40% from a loss of 104.90m to a larger loss of 110.57m despite flat revenues.
Gross margin--
Net profit margin-2,838.89%
Operating margin-3,023.42%
Return on assets-36.20%
Return on equity-42.24%
Return on investment-40.23%
More ▼

Cash flow in USDView more

In 2023, Absci Corp increased its cash reserves by 16.69%, or 12.83m. Cash Flow from Investing totalled 81.94m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 64.64m for operations while cash used for financing totalled 4.48m.
Cash flow per share-0.7902
Price/Cash flow per share--
Book value per share1.95
Tangible book value per share1.54
More ▼

Balance sheet in USDView more

Absci Corp has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 72.36m.
Current ratio6.49
Quick ratio--
Total debt/total equity0.0292
Total debt/total capital0.0284
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.